Sells Proclarix, a protein-based blood test used with prostate-specific antigen testing to help doctors assess prostate cancer risk, to diagnostic laboratories, hospitals and medical centers.
10-K for FY2025, filed Mar 13, 2026We are currently focusing our efforts on commercializing Proclarix.View ↗
Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular…View ↗
The Company derives revenue through sales of its products, which includes Proclarix, its diagnostic product, directly to end users…View ↗
Customers buy Proclarix, with product sales counted when the product is transferred. Proteomedix bills life-sciences customers for development work as it is performed and earns license revenue by granting intellectual-property rights, counted when those rights transfer.
10-K for FY2025, filed Mar 13, 2026Proteomedix provides a range of services to life sciences customers referred to as “Development Services” including testing for biomarker…View ↗
Completion of the service and satisfaction of the performance obligation under a SOW is typically evidenced by access to the data or test…View ↗
The Company derives revenue through sales of its products, which includes Proclarix, its diagnostic product, directly to end users…View ↗
The Company generates other revenue including license revenue through agreements that grant third parties rights to use its intellectual…View ↗
$815.4K
10-K for FY2025, filed Mar 13, 2026
$815.4K ↗
Proclarix is sold directly to end users such as laboratories, hospitals and medical centers, and to distributors. Tests are run through hospital or commercial laboratories serving clinical urology centers; lab networks also reach urologists and general practitioners in private practice.
10-K for FY2025, filed Mar 13, 2026The Company derives revenue through sales of its products, which includes Proclarix, its diagnostic product, directly to end users…View ↗
Market adoption of a new test is driven by KOLs and clinical urology centers. Publication of clinical studies proving the medical benefit…View ↗
General practitioners recruit patients for screening and decide whether to refer a patient to a specialist. They have an important…View ↗
No. It lost $14M in FY2025.
10-Q for Q3 FY2026, filed Nov 16, 2026
−$31.6MView ↗
8-K, filed Nov 6, 2026
On November 4, 2026, Onconetix, Parent, the Seller, and Realbotix (the “Parties”) entered into the First Amendment to the Share Exchange…View ↗
8-K, filed Apr 24, 2026
Effective on April 20, 2026, Andrew Oakley and Thomas Meier notified the Board of Directors (the “Board”) of Onconetix, Inc, a Delaware…View ↗
From vaccine research to prostate diagnostics
The older report described preventive vaccine research across infectious diseases and a vaccine pipeline; the latest report focuses on commercializing Proclarix, a prostate cancer blood test, and says vaccine discovery and development programs were halted.
10-K for FY2022, filed Mar 9, 2023
Competes with Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, OPKO Health, Cleveland Diagnostics, Gen-Probe, Hologic, MdxHealth, Exosome Diagnostics, Bio-Techne, and A3P Biomedical
10-K for FY2025, filed Mar 13, 2026There are a number of tests already on the market or in clinical testing or commercial development that are also intended to triage…View ↗
Loading...